Pratap, Jitesh <br/><br/>
The histone deacetylase inhibitor, vorinostat, reduces tumor growth at the metastatic bone site and associated osteolysis, but promotes normal bone loss.  [electronic resource] 

 -  Molecular cancer therapeutics  Dec 2010 
 - 3210-20 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural 
<br/><br/><label>ISSN: </label>1538-8514 
<br/><br/><label>Standard No.: </label>10.1158/1535-7163.MCT-10-0572  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Animals<br/>Bone Neoplasms--complications<br/>Bone Resorption--complications<br/>Bone and Bones--diagnostic imaging<br/>Cell Line, Tumor<br/>Cell Proliferation--drug effects<br/>Extremities--pathology<br/>Histone Deacetylase Inhibitors--chemistry<br/>Humans<br/>Hydroxamic Acids--chemistry<br/>Mice<br/>Mice, SCID<br/>Osteolysis--complications<br/>Radiography<br/>Tumor Burden--drug effects<br/>Tumor Microenvironment--drug effects<br/>Vorinostat<br/>Xenograft Model Antitumor Assays